Pharma BD Deal Intelligence

Novo A/S (Novo Holdings) / Xellia Pharmaceuticals

2013 · Take-Private · $700M · Complete

Announcement Sentiment

Strongly positive

Novo A/S acquired Xellia Pharmaceuticals from 3i and other shareholders for ~$700M; one of Novo Holdings' largest disclosed investments at the time.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Announced May 21, 2013
Closed Sep 30, 2013
Deal value $700M
Deal type Take-Private
Therapeutic area Hospital anti-infectives
Indications Hospital anti-infectives
Key assets Anti-infective specialty injectables (vancomycin, colistimethate, daptomycin)
Mechanism Glycopeptide, polymyxin, lipopeptide antibiotics (specialty/generic)